New research suggests that analyzing genetic changes found in the bloodstream may help doctors predict which chemotherapy regimens will work for some patients.
Dr. D’Angelica – who treats patients with liver, pancreatic, and bile duct cancers – discusses the expertise of Memorial Sloan-Kettering surgeons, who routinely perform complex procedures.
Medical oncologist Kenneth Yu spoke about a study he led that suggests that a simple blood test may be able to predict which chemotherapy regimen will work for some patients with pancreatic cancer.
Memorial Sloan-Kettering Board member David M. Rubenstein spoke about his $10 million contribution to establish a new pancreatic cancer research center at the hospital, and Department of Surgery Vice Chair Ronald DeMatteo commented on the need for progress against the deadly disease.
Despite having the same name, the diseases that killed Steve Jobs and 2011 Nobel Prize winner Ralph Steinman are two different kinds of cancer. Medical oncologist Leonard Saltz explains.
